12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fosbretabulin: Phase II/III data

OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif.
Product: Fosbretabulin ( Combretastatin A4P, Zybrestat))
Business: Cancer
Molecular target: Tubulin
Description: A4 prodrug phosphatase-activated tumor vascular targeting agent
Indication: Treat advanced anaplastic thyroid cancer (ATC)
Endpoint: Overall survival (OS)
Status: Phase II/III data
Milestone: NA
In the Phase II/III FACT trial in 80 patients, weekly Zybrestat...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >